MLTX vs. QURE
MLTX (MoonLake Immunotherapeutics) and QURE (uniQure N.V.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MLTX returned 12.25%/yr vs -5.87%/yr for QURE. At a 0.20 correlation, their price movements are largely independent.
Performance
MLTX vs. QURE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MLTX achieves a 36.57% return, which is significantly higher than QURE's 12.83% return.
MLTX
- 1D
- 0.56%
- 1M
- 5.51%
- YTD
- 36.57%
- 6M
- 19.44%
- 1Y
- -61.60%
- 3Y*
- -14.95%
- 5Y*
- 12.25%
- 10Y*
- —
QURE
- 1D
- 2.08%
- 1M
- -2.39%
- YTD
- 12.83%
- 6M
- 24.02%
- 1Y
- 56.34%
- 3Y*
- 11.25%
- 5Y*
- -5.87%
- 10Y*
- 8.62%
MLTX vs. QURE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
MLTX MoonLake Immunotherapeutics | 36.57% | -75.66% | -10.33% | 475.14% | 6.17% | -13.02% | 8.39% |
QURE uniQure N.V. | 12.83% | 35.50% | 160.86% | -70.14% | 9.31% | -42.60% | -7.52% |
Correlation
The correlation between MLTX and QURE is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Oct 21, 2020 | 0.20 |
Fundamentals
MLTX:
$1.28B
QURE:
$1.69B
MLTX:
-$3.90
QURE:
-$3.58
MLTX:
5.05
QURE:
11.34
MLTX:
$0.00
QURE:
$18.09M
MLTX:
-$1.49M
QURE:
$13.42M
MLTX:
-$179.84M
QURE:
-$164.53M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MLTX vs. QURE — Risk / Return Rank
MLTX
QURE
MLTX vs. QURE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and uniQure N.V. (QURE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MLTX | QURE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.74 | ||
| Sortino ratioReturn per unit of downside risk | -2.15 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 1.43 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | -0.69 | 0.65 | -1.34 |
| Martin ratioReturn relative to average drawdown | -0.98 | 1.06 | -2.03 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| MLTX | QURE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.53 | 0.21 | -0.74 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.14 | -0.04 | +0.17 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.07 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.12 | 0.05 | +0.07 |
Drawdowns
MLTX vs. QURE - Drawdown Comparison
The maximum MLTX drawdown since its inception was -90.22%, smaller than the maximum QURE drawdown of -95.40%. Use the drawdown chart below to compare losses from any high point for MLTX and QURE.
Loading charts...
Drawdown Indicators
| MLTX | QURE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.22% | -95.40% | +5.18% |
Max Drawdown (1Y)Largest decline over 1 year | -89.93% | -87.21% | -2.72% |
Max Drawdown (3Y)Largest decline over 3 years | -90.22% | -87.21% | -3.01% |
Max Drawdown (5Y)Largest decline over 5 years | -90.22% | -90.11% | -0.11% |
Max Drawdown (10Y)Largest decline over 10 years | — | -95.40% | — |
Current DrawdownCurrent decline from peak | -71.81% | -67.15% | -4.66% |
Average DrawdownAverage peak-to-trough decline | -29.24% | -56.58% | +27.34% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 63.21% | 53.50% | +9.71% |
Volatility
MLTX vs. QURE - Volatility Comparison
The current volatility for MoonLake Immunotherapeutics (MLTX) is 18.65%, while uniQure N.V. (QURE) has a volatility of 28.01%. This indicates that MLTX experiences smaller price fluctuations and is considered to be less risky than QURE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MLTX | QURE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.65% | 28.01% | -9.36% |
Volatility (6M)Calculated over the trailing 6-month period | 55.24% | 92.44% | -37.20% |
Volatility (1Y)Calculated over the trailing 1-year period | 115.84% | 273.61% | -157.77% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.15% | 154.08% | -62.93% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.45% | 119.92% | -33.47% |
Dividends
MLTX vs. QURE - Dividend Comparison
Neither MLTX nor QURE has paid dividends to shareholders.
Financials
MLTX vs. QURE - Financials Comparison
This section allows you to compare key financial metrics between MoonLake Immunotherapeutics and uniQure N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MLTX and QURE have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
QURE has higher volatility (28.01%) compared to MLTX (18.65%). In terms of maximum drawdown, MLTX dropped -90.22% vs QURE's -95.40%.
QURE currently has the higher Sharpe Ratio (0.21 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MLTX and QURE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer